EHA 2023 | Ropeginterferon alfa-2b in patients with pre-fibrotic primary MF & DIPSS low/intermediate-1 risk MF
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, discusses the results of a study evaluating the safety and efficacy of ropeginterferon alfa-2b in patients with pre-fibrotic primary myelofibrosis (MF) and DIPSS low/intermediate-1 risk MF. Dr Gill highlights the key primary and secondary endpoints of this study, and further discusses the main findings. Results demonstrated that ropeginterferon alfa-2b is safe and well-tolerated, with hematologic responses improving over time. Dr Gill further discusses the toxicity profile of this agent, and concludes by summarizing the molecular responses observed in patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Disclosures: Consultancy and advisory board – BMS, GSK, Novartis, Pfizer, PharmaEssentia; Investigator-initiated study collaboration – Imago Biosciences, Novartis, PharmaEssentia
